Pneumoproteins KL ‐6 and CCL‐18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis

ConclusionIn a rigorously ‐conducted clinical trial for SSc‐ILD, KL‐6 and CCL‐18 levels correlated with ILD severity and declined with immunosuppression. Patients with higher baseline KL‐6 and CCL‐18 levels were more likely to experience disease progression despite treatment. KL‐6 and CCL‐18 could be used to identify patients with a progressive ILD phenotype who may benefit from a more aggressive initial treatment approach.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - June 23, 2019 Category: Rheumatology Authors: Elizabeth R. Volkmann, Donald P. Tashkin, Masataka Kuwana, Ning Li, Michael D. Roth, Julio Charles, Faye N. Hant, Galina S. Bogatkevich, Tanjina Akter, Grace Kim, Jonathan Goldin, Dinesh Khanna, Philip J. Clements, Daniel E. Furst, Robert M. Tags: Full Length Source Type: research